Showing 2651-2660 of 3039 results for "".
- Regenxbio Announces Presentations at the American Academy of Ophthalmology 2020 Annual Meetinghttps://modernod.com/news/regenxbio-announces-presentations-at-the-american-academy-of-ophthalmology-2020-annual-meeting/2478516/Regenxbio announced that two oral presentations will be presented at the American Academy Ophthalmology (AAO) 2020 Annual Meeting, taking place November 13-15, 2020 in a virtual format. The first presentation will feature data from the RGX-314 phase 1/2 subret
- Allergan to Share New Data at American Academy of Ophthalmology (AAO) 2020 Virtual Meetinghttps://modernod.com/news/allergan-to-share-new-data-at-american-academy-of-ophthalmology-aao-2020-virtual-meeting/2478510/Allergan, which is now part of AbbVie, announced that it will present new data advancing scientific understanding of an IOP-lowering treatment in glaucoma and evaluating an investigational treatment for presbyopia at American Academy of Ophthalmology (AAO) 2020 virtual meeting (November 13-15).</
- Avellino Introduces Multiplex Respiratory Panel for Simultaneous Detection of COVID-19 and Influenzahttps://modernod.com/news/avellino-introduces-multiplex-respiratory-panel-for-simultaneous-detection-of-covid-19-and-influenza/2478505/Avellino announced that the company has developed a novel multi-panel RT-PCR-based virus assay, AvellinoCoV2-Respiratory, which has been validated following the FDA’s Policy for Diagnostics Testing in Laboratories Certified to Perform High-Complexity Testing CLIA guidelines. The AvellinoCoV
- Oxurion NV Confirms New Patents for THR-687 Issued by European and US Patent Officeshttps://modernod.com/news/oxurion-nv-confirms-new-patents-for-thr-687-issued-by-european-and-us-patent-offices/2478504/Oxurion NV announced a strengthening of its intellectual property (IP) portfolio governing THR-687, an integrin antagonist being developed for the treatment of DME. The European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO) have both issued new composition-o
- How Best to Combat Post-Keratoplasty Infections Isn’t Always Clearhttps://modernod.com/news/how-best-to-combat-post-keratoplasty-infections-isnt-always-clear/2478503/Infection is one of the most dreaded complications after ocular surgery. Although it is considered rare, the rate of fungal infections after corneal transplantation is nonetheless increasing in the United States. As detailed in a recent r
- Pfizer Goes Solo on U.S. Shot Distribution, Opting Out of Government Channelshttps://modernod.com/news/pfizer-goes-solo-on-u-s-shot-distribution-opting-out-of-government-channels/2478499/Pfizer had already made it quite clear that it doesn’t need the U.S. government to help distribute its COVID-19 vaccine, should it be authorized by the FDA. Now it’s putting an exclamation point on that declaration, according to a FiercePharma
- Clots, Strokes And Rashes. Is COVID-19 A Disease Of The Blood Vessels?https://modernod.com/news/clots-strokes-and-rashes-is-covid-19-a-disease-of-the-blood-vessels/2478497/Whether it’s strange rashes on the toes or blood clots in the brain, the widespread ravages of COVID-19 have increasingly led researchers to focus on how the novel coronavirus sabotages the body’s blood vessels, according to an NPR
- Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for Lytenava for Retinal Diseaseshttps://modernod.com/news/outlook-therapeutics-completes-patient-enrollment-of-open-label-safety-study-for-lytenava-for-retinal-diseases/2478490/Outlook Therapeutics announced the completion of patient enrollment for its planned open-label safety study evaluating ONS-5010/Lytenava (NORSE THREE). Patient enrollment for the study was completed in less than 1 month, ahead of the planned 4-month enrollment schedule.
- RegeneRx Joint Venture Enrolls Last Subject in Phase 3 Dry Eye Trialhttps://modernod.com/news/regenerx-joint-venture-enrolls-last-subject-in-phase-3-dry-eye-trial/2478468/RegeneRx Biopharmaceuticals announced that its joint venture, ReGenTree LLC, has enrolled the last of 700 subjects in the ARISE-3 phase 3 clinical trial for dry eye syndrome. Completion of treatment and follow-up for the last subject is anticipated to be by the end of Novem
- UK Study Finds Evidence of Waning Antibody Immunity to COVID-19 Over Timehttps://modernod.com/news/uk-study-finds-evidence-of-waning-antibody-immunity-to-covid-19-over-time/2478463/Antibodies against the novel coronavirus declined rapidly in the British population during the summer, a study found on Tuesday, suggesting protection after infection may not be long lasting and raising the prospect of waning immunity in the community, according to a Reuters